Objective: To determine whether dosage adjustment of enoxaparin during pregnancy, to maintain a peak anti-Xa of 1.0 to 1.2 U/mL, is safe for women with mechanical prosthetic heart valves (MPHV). Design: A prospective observational study. Setting: This study was performed at Charlotte Maxeke Johannesburg Academic Hospital from 2007 to 2009. Population: Fifteen women with MPHVs. Methods: Women were treated with enoxaparin with dosage adjustment to achieve a peak anti-Xa of 1.0 to 1.2 U/ mL. Main Outcome Measures: Main outcomes measured were prosthetic valve thrombosis, bleeding, and maternal mortality. Results: There was no maternal mortality. None of the women developed valvular thrombosis during pregnancy. In all, 2 women developed epistaxis and another developed spotting per vaginum. Conclusion: Our data show that enoxaparin may be administered safely during pregnancy to pregnant women with MPHV when there is dosage adjustment throughout pregnancy to maintain an anti-Xa of 1.0 to 1.2 U/mL.
Introduction
Mechanical prosthetic heart valves (MPHV) are still in use in women of childbearing age. This is because these valves have excellent long-term durability, whereas the alternative bioprosthetic valves are associated with a high rate of structural valvular damage (SVD), 1 which is further accelerated by pregnancy. 2 The continued use of mechanical valves is despite the fact that bioprosthetic valves confer the significant advantage of not requiring anticoagulant prophylaxis. In contrast, mechanical prosthetic valves are associated with increased thrombogenicity requiring anticoagulant prophylaxis.
Mechanical prosthetic heart valves are of 3 main types, the cage-ball valves such as the Starr-Edwards valve, the tilting disc valves such as the Bjork-Shiley, and the Medtronic valves and the bileaflet valves such as the St Jude's Medical valve. Greater thrombogenicity is associated with the older generation valves (Starr-Edwards and Bjork-Shiley) compared to the newer generation valves (St Jude's Medical and Medtronic) and with a prosthetic valve in the mitral as opposed to the aortic position. 3 Options for anticoagulation comprise oral coumarin therapy with warfarin and subcutaneous injection with unfractionated heparin (UFH) or low-molecular-weight heparin (LMWH). Warfarin therapy throughout pregnancy is believed to be most efficacious in the prevention of the maternal thromboembolic disease for patients with MPHV. Unfortunately evidence has shown that this drug may be associated with fetal morbidity and mortality described in the literature as ''warfarin embryopathy.'' 4 Unfractionated heparin is an alternative therapy in women who elect to avoid treatment with warfarin, especially during the first-trimester. However, 2 retrospective surveys reported a high incidence of valve thrombosis in pregnant women with oldgeneration MPHV treated with fixed-or adjusted-dose subcutaneous UFH. 5, 6 The efficacy of adjusted-dose subcutaneous heparin has not been definitively established though.
Low-molecular-weight heparins are glycosaminoglycan molecules that exert their anticoagulant activity by binding to antithrombin and causing a conformational change that greatly enhances the ability of antithrombin to bind to and inhibit the action of the activated coagulation factor X (factor Xa). The LMWHs have generated a significant amount of interest in recent years, the reason for this is 2-fold: first, the improved pharmacokinetics and side effect profile of the LMWHs compared to UFH and second, the potential benefits in pregnancy. Low-molecular-weight heparins have been shown to cause less heparin-induced thrombocytopenia than UFH. In addition, a study done in pregnancy showed that LMWH usage was associated with significantly less osteoporosis when compared to UFH usage. 7 A number of studies done on LMWH use in pregnancy show that the LMWHs are generally safe when administered for thromboprophylaxis in pregnancy. 8 Lowmolecular-weight heparin has an average molecular weight of 5000 and has been shown not to cross the placenta; hence, its use in pregnancy is safe for the foetus. 9 When monitoring of anti-factor Xa (anti-Xa) levels are indicated, such as for maternal patients with MPHV, the peak anti-Xa activity should be measured 3 to 4 hours after subcutaneous LMWH injection.
Reports of treatment failure such as thrombosis of prosthetic heart valves in pregnant women on LMWH in addition to concerns about possible teratogenicity raised questions regarding the safety of LMWH. This resulted in a ''warning'' being issued by a LMWH manufacturer regarding the use of LMWH in pregnant women with MPHV. 10 As LMWH does not cross the placenta, it is implausible that it causes fetal morbidity or mortality. 9 Subsequent to the warnings release, a cardiology consensus statement regarding the use of LMWH in pregnancy was issued stating it ''should more appropriately be considered an unproven and imperfectly studied alternative among a trio of suboptimal and potentially unfavorable options (warfarin, UFH, and LMWHs).'' 11 A number of reviews have stated that there are presently no good data documenting the use of LMWH in pregnant women with MPHV and there have been calls for appropriately designed studies to investigate this therapeutic option. One review concluded that LMWH could be the best option of the 3 treatment options available but that all 3 options have still been understudied. 11 More recently, the earlier warning by the LMWH manufacturer has been rephrased to ''use of Lovonox (LMWH) for thromboprophylaxis in pregnant women with MPHV has not been adequately studied.'' 12 The 8th American College of Chest Physicians (ACCP) guidelines recommend the use of LMWH at a dose aiming to achieve peak anti-Xa levels of *1.0 U/mL as one of the treatment options. 13 
Objective
To determine whether the use of the LMWH, enoxaparin, is safe for pregnant women with MPHV during pregnancy when used with dosage adjustment to maintain a peak anti-Xa of 1.0 to 1.2 U/mL. Key outcomes measured were prosthetic valve thrombosis, bleeding, and maternal mortality.
Materials and Methods
This was a prospective observational study performed at Charlotte Maxeke Johannesburg Academic Hospital from 2007 to 2009. Our sample consisted of 15 consecutive pregnant women. The women in our study were 18 years and older with known MPHV in the mitral and/or aortic position (single or double). Most of these women were either attending the anticoagulation clinic at Charlotte Maxeke Johannesburg Academic Hospital or Chris Hani Baragwanath Hospital for monitoring of warfarin therapy efficacy prior to conception. Written informed consent was obtained prior to any protocol-specific procedures. Other inclusion criteria included cardiac assessment to confirm clinical stability, sinus rhythm as well as ability to administer medication subcutaneously at home and a normal platelet count for pregnancy (>100 Â 10 9 /L).
Women with cardiac instability, infective endocarditis, a known thrombophilic state, an inherited condition predisposing to bleeding, and any women with hemolysis were excluded from our study. Women were removed from therapy for noncompliance on treatment or inability to administer medication at home and the development of thrombocytopenia. Any women who were treated with enoxaparin for 2 weeks or less were not included in the write up of this study. Aspirin was not routinely given to the women in our study. Any other medication inhibiting platelet function such as other nonsteroidal anti-inflammatory drugs and medication that would interact with enoxaparin or interfere with evaluation of the clinical response (systemic glucocorticoids and thrombolytics) were not administered.
The experimental protocol observed was as follows. Women were admitted as soon as they discovered they were pregnant or whenever they presented to the hospital during pregnancy. All patients signed written consent to take part in the study. Women were started at a dose of enoxaparin calculated at 1 mg/kg twice daily. The dose of enoxaparin was then adjusted to achieve a peak anti-Xa level (3 hours postdose) of more than 1.0 U/mL and less than 1.2 U/mL. The women were taught how to inject themselves in the hospital and were then discharged home where they injected themselves twice a day (12 hourly) with enoxaparin until just prior to delivery. The women attended the antenatal clinic weekly, where they had a full clinical examination and blood was taken for peak anti-Xa levels, which was measured at the NHLS (National Health Laboratory Service) Hematology Coagulation Laboratory at Charlotte Maxeke Johannesburg Academic Hospital. The dose of enoxaparin was adjusted weekly to maintain the therapeutic peak anti-Xa level of 1.0 to 1.2 U/mL for the duration of pregnancy.
Anti-Xa values outside the target range would result in an either upward or downward adjustment in the dose of enoxaparin by 10 mg. An echocardiogram to exclude valvular thrombosis was performed monthly.
''Major'' bleeding was defined as bleeding resulting in a drop in the hemoglobin concentration by !2 g/dL or as bleeding requiring transfusion of at least 2 units of packed red blood cells. Bleeding not fulfilling these criteria was defined as ''minor.''
A prospective control arm of pregnant women taking warfarin was not undertaken as we felt it was unethical to purposefully expose fetuses to a drug with known teratogenic potential.
Results
A total of 18 consecutive women met the inclusion criteria and consented to be part of the study. In all, 2 of these women were not included in the write up of this study as they were treated with adjusted-dose enoxaparin therapy for 2 weeks or less before delivery. A further patient was not included in the write up of this study due to insufficient data. All 3 of these patients did not develop any thrombotic or hemorrhagic complications during enoxaparin exposure in pregnancy. No patient who met the inclusion criteria declined to be part of the study. An additional maternal patient with a MPHV did not meet the inclusion criteria as she was younger than 18 years of age. Table 1 illustrates baseline information of our patient group including the type of mechanical prosthetic valve present. It also shows the duration of the various anticoagulation therapies used during pregnancy.
The average age was 26.3 years (median 24 years); there were 6 primigravidas and 9 multigravidas. All of the women were New York Heart Association (NYHA) class 1 to 2. One woman had epilepsy and was being treated with carbamazepine (patient 1), whereas another patient (patient 13) had human immunodeficiency virus (HIV) infection and was receiving antiretroviral therapy. In all, 6 of the 15 women had double prosthetic valves with an aortic MPHV in addition to a mitral MPHV. All the women had bileaflet MPHV (secondgeneration valves). The average time to presentation to our unit and conversion to enoxaparin was 14.7 weeks (median 17 weeks). The total combined period of time that our women were exposed to adjusted-dose enoxaparin during pregnancy was 344 weeks.
Two women were not on any anticoagulation during pregnancy prior to presentation for 15 weeks (patient 2) and 23 weeks (patient 7). Figure 1 shows the duration of adjusted-dose enoxaparin exposure relative to the duration of prior anticoagulation given in pregnancy. Figure 2 shows the average anti-Xa readings recorded throughout pregnancy with the 95% confidence interval. All the average readings recorded were maintained within the target range of 1 to 1.2 U/mL throughout pregnancy. Figure 3 shows the average enoxaparin doses in milligrams recorded throughout pregnancy with the 95% confidence interval. Table 2 demonstrates adverse maternal outcomes. Maternal morbidity was expressed as valve thrombosis, bleeding, and cardiac, obstetric, or other complications. Maternal mortality is also recorded.
None of the women developed prosthetic valve thrombosis during pregnancy and there was no maternal mortality. Patient 9 developed asymptomatic pannus that was detected postdelivery by echocardiography. She subsequently also developed valvular thrombosis on the same valve 4 weeks later, which was associated with significant shortness of breath. This occurred 2 days after the enoxaparin was stopped, despite the patient being therapeutic on warfarin therapy at the time (6 weeks postpartum). She had an uneventful valve replacement.
Patient 13 developed numbness and tingling of the left arm. This lasted about 6 hours and occurred at 19 weeks of gestation. On further enquiry, it was revealed that she had suffered similar events since childhood prior to the insertion of the prosthetic valve. For completeness, echocardiography was carried out, which revealed a normal functioning valve with no evidence of valvular thrombosis. A normal D-dimer level also confirmed the absence of thrombotic event. Her anti-Xa level at the time was 1.18 U/mL. This episode did not recur during her pregnancy.
Patient 11 had 4 episodes of epistaxis while on enoxaparin in this pregnancy. She presented with a history of epistaxis since childhood. Each episode of epistaxis in this pregnancy involved the left nostril (this was the same nostril from which she had had a long history of bleeding) and occurred when the ambient temperature was high. The severity of the bleeding varied from a few drops to an episode, which required nasal packing with gauze soaked with zinc oxide paste in the casualty department. However, the patient did not fulfill the criteria for major bleeding. A peak anti-Xa taken soon after presentation revealed an anti-Xa of 1.35 U/mL, mildly greater than the therapeutic range. She was subsequently treated with saline nasal drops and chloramphenicol ointment and her enoxaparin dose was adjusted downward to return into the therapeutic range. This patient developed mild itching at the site of enoxaparin injection. This may have represented a mild allergy to the drug. This was treated with a topical antihistamine ointment with some improvement. Patient 15 had no previous history of epistaxis, however, developed an episode of epistaxis during her pregnancy. The bleeding was defined as minor; however, she required nasal packing. A peak anti-Xa revealed a result of 1.79 U/mL at the time of bleeding. Her dose of enoxaparin was reduced to achieve the target anti-Xa level. She did not have any further epistaxis during her pregnancy. One woman developed spotting with a few drops of blood passed per vaginum (patient 1). No other potential side effects of enoxaparin use were noted such as heparin-induced thrombocytopenia and there was no clinical evidence of vertebral osteoporosis.
Discussion
The use of LMWH in pregnant women with mechanical prosthetic valves has been a subject of much controversy. A review of 81 pregnancies in 75 women with MPHV treated with LMWH during pregnancy done by Oran et al 14 reported an 8.6% rate of valve thrombosis. This rate of valve thrombosis is unacceptably high especially as valve thrombosis in these women is often associated with maternal and fetal mortality. However, careful review of the cases of valve thrombosis reported by Oran et al indicated a consistent pattern; most, if not all, of these cases were associated with an inadequate dose of LMWH, lack of monitoring, or subtherapeutic anti-Xa levels.
For this reason, strict monitoring of anti-Xa levels was performed in our study and the dose of LMWH was subsequently adjusted to maintain the high level of anticoagulation required to keep the anti-Xa at 1.0 to 1.2 U/mL throughout pregnancy.
Our data show that enoxaparin may be efficacious in the prevention of cardiac valve thrombosis in this high-risk group of women when associated with anti-Xa monitoring and dosage adjustment. A similar finding has been shown by 2 other studies also performed in maternal patients with MPHV in Auckland 15 and in London. 16 The Auckland study used adjusted-dose enoxaparin therapy to achieve a peak anti-Xa of 0.7 to 1.2 U/mL at 4 hours postdose. This was a large study (n ¼ 47) that showed a 10.6% rate of valve thrombosis related to enoxaparin therapy. The reasons outlined for valvular thrombosis were subtherapeutic anti-Xa levels and poor compliance. The London study used adjusted-dose dalteparin and enoxaparin to achieve a peak anti-Xa of 1 to 1.2 U/mL throughout pregnancy 4 hours postdose. This study showed an 8.3% (1/12) rate of valve thrombosis. The reason stated for this was that the patient had a subtherapeutic anti-Xa level and frequent monitoring of the anti-Xa was not possible. A further complicating factor was that this patient also had an underlying thrombophilic state (heterozygous prothrombin G20210A gene mutation). It is not clear though how often patients had anti-Xa monitoring in this study. Possible reasons why the rate of valvular thrombosis observed in our study was lower than that observed in these studies could be that there was a higher target range for the peak anti-Xa in our study in comparison to the Auckland study and more frequent anti-Xa monitoring was performed in our study (weekly as opposed to monthly). Both these factors could have reduced the likelihood of our patients developing subtherapeutic anti-Xa levels and subsequent valve thrombosis. Trough anti-Xa levels were, however, not measured in our study and there are currently no good data to show how frequently anti-Xa levels should be monitored for this patient group. More frequent antenatal visits may have also helped with patient compliance. The limitations of our study though are that there was no control group and it was not composed of a large sample size. The results of these studies would support the recommendation of LMWH as a treatment option for this patient group in the 8th ACCP guidelines as no patients developed valvular thrombosis on enoxaparin while the anti-Xa was in the therapeutic range. Elkayam et al make a distinction between the risk posed to pregnant women with first-generation prosthetic valves in the mitral position compared to the risk posed to those with second-generation prosthetic valves in the mitral position or any mechanical prosthetic valve in the aortic position. They suggest that the former group have a higher risk of thrombosis than latter group. 3 All the women in our study had secondgeneration prosthetic valves and based on this risk stratification, despite still being high-risk they are at a lower risk than the above described group of women with older generation prosthetic valves. Appropriate studies are required to assess the efficacy of LMWH in pregnant women with the firstgeneration prosthetic valves. However, due to their greater thrombogenicity, these first-generation prosthetic valves are no longer as commonly used as the second-generation prosthetic valves in our center.
Maintenance of the anti-Xa at 1.0 to 1.2 U/mL throughout pregnancy results in a high degree of anticoagulation, thus a higher theoretical risk of bleeding. Over-anticoagulation can result in bleeding as was observed in one of our patients. None of the women in our study, however, developed a major bleed requiring blood transfusion as a complication of enoxaparin therapy during their pregnancy. In all, 1 of the 2 women with epistaxis already had a predisposition to nose bleeding which was exacerbated by the enoxaparin. The general lack of bleeding is a positive finding which further supports the use of enoxaparin in the women studied.
Warfarin therapy for pregnant women with MPHVs is efficacious in the prevention of cardiac valve thrombosis with the reported overall maternal mortality reported as 2.9%. 17 Until a randomized controlled study is done to compare the use of adjusted-dose enoxaparin to warfarin, it will be difficult to say that enoxaparin is at least as efficacious as warfarin in the prevention of maternal thromboembolic disease in this patient group. Studies such as this one are, however, beginning to show that adjusted-dose enoxaparin may have a significant role to play for these patients in both maternal thromboprophylaxis as well as the prevention of fetal morbidity and mortality related to oral anticoagulant use.
Conclusion
Our data show that enoxaparin may be administered safely in pregnant women with MPHV when there is dosage adjustment throughout pregnancy to maintain an anti-Xa of 1.0 to 1.2 U/mL. Women with a significant bleeding tendency from prior to starting anticoagulation should be monitored closely to exclude bleeding as a complication of LMWH therapy.
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